At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 221 enrolled
Drug / intervention
Eplerenone +1 moredrug
Likely dose
Eplerenone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted May 4, 2010·Updated Dec 22, 2020
In Brief
A Phase 3 clinical trial evaluating Eplerenone and Placebo for Heart Failure. Completed, enrolled 221 participants across 54 sites.
Detailed Summary
A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJul 2010
Primary CompletionSep 2015
TodayJul 2026
First PostedMay 4, 2010
Enrollment StartJul 1, 2010
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 16.2 years ago
Interventions
Eplerenonedrug
Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
Placebodrug
Placebo once daily or every once daily